Perion enters a $420 million all-cash merger agreement with Affle, with shareholders set to receive $11.70 per share, a 34.5% premium.
Read MoreNasdaq Stock Market
Vyome Therapeutics Completes Merger with ReShape Lifesciences; Nasdaq Debut Under Ticker HIND
Vyome Therapeutics completes merger with ReShape Lifesciences; to trade on Nasdaq as Vyome Holdings (HIND) from August 15, 2025.
Read More

